Summit Therapeutics' Stock Skyrockets After Cancer Drug Outperforms Keytruda in Phase 3 Trial
TL;DR
Summit Therapeutics' stock surged after the company announced that its cancer drug outperformed Keytruda in a Phase 3 trial, just ahead of a major cancer conference in Chicago.
Topics:businessbiotechnology#biotechnology#cancer-drug#keytruda#phase-3-trial#stock-surge#summit-therapeutics
- Summit Therapeutics’ stock soars as biotech says its cancer drug beat Keytruda in Phase 3 Endpoints News
- Why Summit Therapeutics Stock Is Sinking Today Yahoo Finance
- Ivonescimab Monotherapy Decisively Beats Pembrolizumab Monotherapy Head-to-Head, Achieves Statistically Significant Superiority in PFS in First-Line Treatment of Patients with PD-L1 Positive NSCLC in China Business Wire
- Pharma Billionaire's Fortune More Than Doubles In A Day On Cancer Drug Trial News Forbes
- Summit Therapeutics’ stock surges as cancer drug vies with Merck’s Keytruda MarketWatch
Want the full story? Read the original reporting
Read on Endpoints News